The companies on the Global 500 employ 70.2 million people, and their revenue represents more than one-third of the world’s GDP.

Fortune Global 500

With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

The 300 companies on this year’s list brought in over $12.5 trillion in revenue for the latest 12 months, with the median revenue figure at $24 billion.

America's Most Innovative Companies

The corporations on our annual list of the world's 500 largest companies combined to generate $41.7 trillion in revenue over the past year.

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

The 300 companies on this year’s list brought in over $12.6 trillion in revenue for the latest 12 months, with the median revenue figure at $22 billion.

The corporations on our annual list posted aggregate revenues of $41 trillion for the second year in a row.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 25th Fortune World’s Most Admired Companies list suggests that tech giants’ peers respect them as much as ever.

World's Most Admired Companies

The corporations on our annual list of the world’s largest companies delivered a record $41 trillion in aggregate revenues.

G500-2023-McKesson

The drug distributor reported an 11% increase in revenue, driven by strong growth in its U.S. pharmaceutical segment. 
<ul> 
 	<li>McKesson shareholders reaped a 52% return, including dividends, in 2022. That gain was owed in part to shareholders’ growing confidence in the company’s outlook in the wake of a February 2022 legal settlement that resolved several lawsuits against McKesson for its alleged role in facilitating the overprescription of opioids. The company said it continued to dispute those allegations.</li> 
 	<li>In March 2023, McKesson announced a five-year medical equipment and supply contract with the U.S. Department of Veterans Affairs.</li> 
</ul>

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

F500-2023-McKesson

Just as it dominates our economy, Big Tech now dominates Fortune’s annual ranking of corporate reputation.

Aggregate sales hit $37.8 trillion last year—an increase of 19%, the highest annual growth rate in the list’s history.

G500-2022-16-McKesson

The largest U.S. drug distributor, like several of its competitors, remains under fire for its alleged role in America’s destructive opioid epidemic, as plaintiffs and prosecutors accuse it of hiding flaws in its supply chain that made it too easy for doctors to overprescribe and patients to abuse the drugs. In part as a result of a recent settlement with several states, McKesson reported a $4.5 billion loss for the fiscal year ended March 2021. After taking charge as a CDC-appointed centralized distributor for COVID vaccines in the U.S., McKesson had distributed about 246 million doses as of December 2021. McKesson’s oncology tech business, Ontada, joined MYLUNG to advance precision medicine for lung cancer patients.

This year’s Fortune 500 marks the 68th running of the list.

F500 2022 McKesson Corp

The country’s largest drug distributor, like several of its competitors, remains under fire for its alleged role in America’s destructive opioid epidemic, as plaintiffs and prosecutors accuse it of hiding flaws in its supply chain that made it too easy for doctors to overprescribe and patients to abuse the drugs. In part as a result of a recent settlement with several states, McKesson reported a $4.5 billion loss for the fiscal year that ended in March 2021. After taking charge as a CDC-appointed centralized distributor for COVID vaccines in the U.S., McKesson distributed about 246 million doses as of December 2021. McKesson’s oncology technology business, Ontada, joined MYLUNG to advance precision medicine for lung cancer patients.

After a year in which humanity leaned more heavily than ever on tech giants, see which companies topped Fortune's ranking of corporate reputation.

Total revenue for the world’s biggest companies fell 4.8% to $31.7 trillion this year—the first decline in half a decade.

G500-2021-012-McKesson

America’s largest drug distributor—whose fiscal year ended early in the pandemic in March 2020—recorded a 7.8% revenue increase last year, owing to greater volumes and higher prices of the drugs it delivers. As with its two main competitors, Texas-headquartered McKesson continues to battle legal challenges over its role in the nation’s opioid epidemic. In 2020, the company was selected by the U.S. government as the main distributor for the nation’s COVID vaccines.

This year’s Fortune 500 marks the 67th running of the list.

F500 2021-07-McKesson

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune Global 500 generated $33.3 trillion in revenues and $2.1 trillion in profits.

G500-Featured Image-Logo-2020

With new CEO and McKesson veteran Brian Tyler at the helm, the largest U.S. drug distributor recorded 7.8% revenue growth, fueled largely by more sales volume and higher drug prices, as well as by acquisitions. That growth offset the loss of some customers and the price declines of branded drugs going off-patent. The company, which delivers a third of the nation’s drugs and counts Walmart as a customer, saw profits drop due to a variety of impairment charges and costs associated with opioid-related litigation. Along with other drug distributors, McKesson is the subject of a federal criminal investigation and is fighting thousands of lawsuits over its alleged role in the nation’s opioid epidemic. In February, 21 states rejected a proposed $18 billion settlement with McKesson and the U.S.’s two other largest drug wholesalers.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-007-McKesson

With new CEO and McKesson veteran Brian Tyler at the helm, the nation’s largest drug distributor recorded 2.9% revenue growth, fueled largely by more sales and higher drug prices, as well as acquisitions. That growth offset the loss of some customers and the price declines of branded drugs going off-patent. The company, which delivers a third of the nation’s drugs and counts Walmart as a customer, saw profits drop due to a variety of impairment charges and costs associated with opioid-related litigation. Along with other drug distributors, McKesson is the subject of a federal criminal investigation and is fighting thousands of lawsuits over its alleged role in the nation’s opioid epidemic. In February, 21 states rejected a proposed $18 billion settlement with McKesson and the U.S.’s two other largest drug wholesalers.

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune Global 500 generated $27.7 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 65th running of the list.

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 64th running of the list.

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 63rd running of the list.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune Global 500 generated $27.6 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 62nd running of the list.

Business insiders have spoken: Asked which companies they most admire, more than 4,100 executives, directors, and analysts chose these top 50 All-Stars.

The world's 500 largest companies generated $31.2 trillion in revenues and $1.7 trillion in profits in 2014. Together, this year's Fortune Global 500 employ 65 million people worldwide and are represented by 36 countries.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Global business is back. After limping through a worldwide financial crisis and economic slowdown, the 500 largest companies ranked by revenues shattered all sorts of performance records in 2013: They racked up combined revenues of $31.1 trillion, up 2.5% from 2012, and profits soared 27% to nearly $2 trillion. China’s 95 companies (up from 89 last year) posted $5.8 trillion in revenues. The U.S. has four fewer companies on the list than last year but remains (for now) the country leader, with 128 corporations on the list—including No. 1 Wal-Mart Stores—reporting $8.6 trillion in revenues. 

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Sector

Industry

Industry Rank

Previous Industry Rank

Overall Score

Strongest Dimension

Years on list

Previous rank

State

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

McKesson provides health care services in the United States and internationally, operating a number of different businesses including distributing over-the-counter pharmaceutical drugs and other health-care-related products. Its prescription technology services business, meanwhile, serves biopharma and life sciences partners and works with patients to address medication challenges. Its medical-surgical solutions business offers various services to health care providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies, although the company announced plans in 2025 to separate that business.

Q1 2027

Q4 2026

Q3 2026

Q2 2026

Q1 2026

Q4 2025

Q3 2025

McKesson (MCK): Company Profile, Stock Price, News, Rankings

legacy

McKesson

mckesson

Please stand by. Welcome to McKesson's second quarter fiscal 2026 earnings conference call. Please be advised that today's conference is being recorded. At this time, I would like to turn the conference over to Jeni Dominguez, VP of Investor Relations. Please go ahead.

Thank you, operator. Good afternoon and welcome everyone to McKesson's second quarter fiscal 2026 earnings call. Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. Brian will lead off, followed by Britt, and then we'll move on to a question-and-answer session. Today's discussion will include forward-looking statements such as forecasts about McKesson's operations and future results. Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at investor.mckesson.com and to the risk factors section of our most recent annual and periodic SEC filings for additional information concerning risk factors that could cause our actual results to materially differ from those in our forward-looking statements. Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those measures to GAAP results, can be found in today's earnings release and presentation slides.

The presentation slides also include a summary of our results for the quarter and guidance assumptions. With that, let me turn it over to Brian.

Thank you, Jeni. Good afternoon, everyone. Thank you for joining our call today. Earlier today, we reported strong second quarter results, which reflect sustained momentum in our business and the strength of our diversified portfolio. Consolidated revenues in the quarter increased 10% year-over-year to $103 billion, and adjusted earnings per diluted share increased 39% to $9.86. These results demonstrate the impact of focused execution across the enterprise, with notably three of our segments delivering double-digit adjusted operating profit growth as we continue to deliver against our strategic priorities. Given our first-half performance and our confidence in the outlook for the year, we are raising our guidance on adjusted earnings per diluted share to $38.35-$38.85. This builds on the $0.80 increase announced at our Investor Day in September. At the event, we also affirmed our company priorities and highlighted the differentiated capabilities that underpin McKesson's long-term growth.

I'll walk you through our continued progress we achieved in the second quarter. At that conference, we also introduced our new reporting structure that sharpens our strategic alignment and provides enhanced transparency into the growth areas of our business. The newly formed Oncology and Multispecialty segment will focus on accelerating our strategy in the higher growth, higher margin segments. We established the North American Pharmaceutical segment, bringing together our pharmaceutical distribution capabilities in the U.S. and Canada. This quarter marks our first set of results under this structure, and I'm pleased with how our teams have come together to deliver consistent financial performance. We're confident that the new reporting structure will optimize our portfolio management and drive sustainable long-term value creation for shareholders. Britt will share more about the quarterly results in his remarks. Let me start by talking a minute about our people and culture.

Team McKesson is the driving force for the continued innovation and excellence. It is the foundation of everything that we accomplish. Our best talent strategy continues to raise the bar across McKesson and is evident in the way our teams and our Board approach service, integrity, teamwork, and performance. That commitment is exemplified by our Chairman of the Board, Don Knauss, who was recently honored with the B. Kenneth West Lifetime Achievement Award from the National Association of Corporate Directors. This is a well-earned recognition of his leadership, and I am grateful for his many, many contributions to McKesson. We believe that a strong culture is an integral part of our talent strategy, and it is reflected in how we support our communities and our people. In September, McKesson team members came together to participate in our annual Community Impact Days.

We supported more than 60 organizations nationwide, giving back to our communities and reinforcing the values that drive our everyday work. We support and care for our people through extensive resources and programs. In October, employees across McKesson took part in our annual Wellness Day. We refer to it as Your Day, Your Way. It is now in its fifth year, and it underscores our continuing commitment to our team's well-being. Let's move on to our two strategic growth pillars, Oncology and Multispecialty, and our biopharma services. Our differentiated specialty platform remains a central pillar of our growth strategy and is now reported within the newly established Oncology and Multispecialty segment. Our differentiated capabilities have us well-positioned to advance cancer care and expand into other therapeutic areas through scale, connectivity, and innovation. Foundational to our Oncology and Multispecialty business is our unparalleled distribution breadth.

Specialty is a growing market with many unique medications and distribution requirements. We have market-leading capabilities and scale through our strong presence in the community provider setting, serving more than 14,000 providers across a wide range of specialties. Complementary to the core distribution capabilities are our group purchasing organizations, specialty pharmacy offerings, and infusion management services. Our diverse capabilities enable us to support a wide range of customers with varying needs and accessing specialty meds, including innovative therapies that are transforming care. This includes the launch and commercialization of cell and gene therapies. In August, we launched InspiroCare, a patient hub designed to simplify the complex journey of cell and gene therapies and provide personalized, compassionate support for patients. In September, we opened a world-class cold chain facility dedicated to cell and gene therapy distribution.

12,000 sq ft facility is equipped with ultra-frozen and cryogenic storage technology specifically designed for the unique requirements of these medications, ensuring proper storage and the highest standards of compliance and care. Our best-in-class oncology platform provides support to community providers through a comprehensive suite of services, including practice management, clinical trial access, and industry-leading technology solutions that empower them to deliver world-class care. The US Oncology Network has been leading the cancer care transformation for more than 15 years and is now supporting over 3,300 providers across more than 700 sites across the country. In October, The US Oncology Network formed a collaboration with Blood Cancer United around a shared goal of strengthening cancer care and access to clinical trials close to home. The collaboration will provide personalized clinical trial education as well as clinical trial matching through the Sarah Cannon Research Institute.

It will also offer patient navigation services to facilitate participation in clinical trials for patients with all types of blood cancer. During the second quarter, progress continued with the integration of Florida Cancer Specialists and PRISM Vision, bringing both practice groups onto our distribution and GPO agreements to unlock the full value of our broader services and take advantage of the expanded relationships. PRISM Vision recently expanded its footprint with the addition of Spokane Eye Clinic, located in Spokane, Washington, extending its reach now beyond the Mid-Atlantic region. Spokane Eye Clinic has a growing team of 27 eye care specialists in four clinic locations. It marked an important milestone for PRISM in building a comprehensive national eye care platform and continuing to enhance patient experiences. Let's move on to our biopharma services platform within our Prescription Technology Services segment.

Our leading technology platform is designed to make medicine more accessible and more affordable for everyone. What differentiates McKesson is the breadth and depth of our capabilities to address the most pressing challenges of access and affordability. Our network spans approximately 1 million providers and more than 50,000 pharmacies processing approximately 23 billion transactions annually. This connectivity and scale is the foundation that enables us to streamline access to lifesaving therapies, reduce friction across the healthcare continuum, and deliver measurable impact for our customers and patients. Our platforms combine tech-driven patient support services, automated prior authorization, copay, and voucher programs, all designed to help patients start, stay on, and afford their therapies. We complement these offerings with best-in-class third-party logistics, advanced analytics, and AI-enabled solutions that optimize efficiency and unlock value for our biopharma partners.

This integrated approach positions McKesson as a trusted leader, not only solving today's challenges but continuing to invest in the future, expanding our solutions for specialty therapies, modernizing technology, and leveraging innovation to advance health outcomes for all. Let me touch on our Pharmaceutical distribution business in North America. This is a foundational business that continues to deliver strong growth underpinned by operational discipline and a differentiated value proposition. The sustained momentum of the business, driven by leading scale, strong operating leverage, and robust cash flow generation, enables us to continue to reinvest in the business to advance all of our enterprise priorities. We have made focused and significant investments in automation to support the growing complexity in the supply chain management. These investments improve operating efficiency, enhance customer experience, and unlock productivity in our workforce.

An example of the advanced automation technologies we have implemented is the order storage retrieval system, which has been introduced in facilities across North America. The most recent application being in our U.S. National Redistribution Center, serving as the core of our hub-and-spoke distribution model. This sophisticated system improves our service levels and accuracy, streamlines processes, and expands our storage capacity to better serve our customers. As an example, what would have normally taken eight physical human touches to complete a pick, pack, and ship process now only takes two human touches. We are committed to investing in technology and automation, which will continue to position us for long-term growth in the future. In August, our U.S. pharmaceutical business achieved a major milestone in the implementation of the Drug Supply Chain Security Act.

We are now actively exchanging serialized transaction data with supply chain participants in compliance with these new FDA requirements. Behind this achievement was the extraordinary collaboration across the enterprise, from technology and operations to regulatory affairs and customer support. Throughout this very complex implementation, we maintained exceptional service-level accuracy with almost no disruption to our customers. We're proud to lead in this initiative that will enhance the safety, transparency, and integrity of the pharmaceutical supply chain. Now, let me provide a brief update on our portfolio actions. Our teams continue to actively execute on multiple work streams to separate the Medical-Surgical business, positioning it to become an independent, well-capitalized operating company. As shared in Investor Day, we're targeting to exit the Medical-Surgical Solutions business through an initial public offering.

Following a customary lockup period, we intend to exit our remaining interest through a spinoff or split-off transaction, or possibly a combination of both. We anticipate that this separation could be completed by the second half of calendar 2027, subject, of course, to market conditions and customary regulatory approvals. In summary, McKesson delivered another strong quarter of performance. Our strategy and execution are driving outstanding results, and this momentum continues to build across the enterprise. We operate in a dynamic market and policy backdrop, and we're highly engaged in that process across the organization. Importantly, we're executing from a position of strength and credibility. We remain committed to collaborating closely with policymakers and stakeholders to advocate for changes that align with the values of our company and our good for healthcare.

We're confident that our differentiated capabilities will continue to deliver value to customers and patients and be an important part of addressing healthcare's most pressing challenges. Lastly, I want to thank my fellow McKesson team members for their dedication and their contribution to advancing our mission. Together, we are advancing health outcomes for all, and we are excited about the opportunities that lie ahead. With that, I'll hand it over to Britt for some additional financial details.

Thank you, Brian, and good afternoon. I'm pleased to report another quarter of strong execution and financial performance exceeding our expectations, reflecting the strength of our diversified healthcare platform. My comments today will refer to our adjusted results. I'll begin with our second quarter fiscal 2026 performance, followed by an update on our fiscal 2026 outlook.

As previewed at our Investor Day in September, we implemented a new reporting structure beginning in the second quarter to enhance transparency and sharpen visibility into our growth platforms. This framework highlights the differentiated capabilities within our Oncology and Multispecialty and biopharma services platforms, verticals where McKesson is best positioned to deliver sustainable long-term growth. This realignment reinforces our commitment to discipline execution, strengthens our strategic focus, and accelerates long-term value creation for all stakeholders. Turning now to results for our second quarter, McKesson delivered another strong quarter, achieving record quarterly revenues of $103 billion, an increase of 10% compared to the prior year, driven by robust performance across our portfolio of businesses.

Growth was led by the North American Pharmaceutical segment, reflecting increased prescription volumes from retail national account customers, and by the Oncology and Multispecialty segment, supported by expanded distribution of Oncology and Multispecialty products and contributions from recent acquisitions. Gross profit increased 9% to $3.5 billion, primarily due to strong specialty distribution and provider growth within the Oncology and Multispecialty segment. Operating expenses decreased 1% to $2 billion, reflecting divestitures in our Canadian business and disciplined cost optimization initiatives in the Medical-Surgical Solutions segment. These reductions were partially offset by continued investment in the Oncology and Multispecialty segment, including acquisitions completed in the first quarter of fiscal 2026. Our underlying focus on cost discipline and operational efficiency, powered by a technology-first mindset and AI-driven modernization, continues to create value for all stakeholders. This progress is evident again in the second quarter.

Operating expenses as a percentage of gross profit declined 570 basis points, delivering significant operating leverage as we accelerate and modernize our operations. Operating profit reached a quarterly record of $1.6 billion, an increase of 26% year-over-year, reflecting growth across all operating segments. This strong performance was driven by increased specialty distribution volumes in both the Oncology and Multispecialty and North American Pharmaceutical segments, increased demand for access solutions in our Prescription Technology Solutions segment, and continued benefits from cost optimization initiatives in the Medical-Surgical Solutions segment. The acquisitions of PRISM and Core Ventures in the Oncology and Multispecialty segment contributed approximately 6% to year-over-year growth. Additionally, the sale of an equity investment and market decisions within The US Oncology Network contributed approximately 4%. Excluding these two items, organic growth was approximately 16% in the quarter, underscoring the strength and momentum of our core business.

Interest expense declined 6% to $68 million, resulting from effective cash and portfolio management, including our derivative portfolio. The effective tax rate was 17.5% compared to 21% in the prior year. In the second quarter of fiscal 2026, we recognized net discrete tax benefits of $96 million, primarily related to the release of a valuation allowance compared to net discrete tax benefits of $44 million in the second quarter of fiscal 2025. Second quarter diluted weighted average shares outstanding was 124.4 million, a decrease of 4%.

Second quarter earnings per diluted share increased 39% to $9.86, driven by several key factors: robust core operational performance, contributions from the first quarter acquisitions of PRISM and Core Ventures in our Oncology and Multispecialty segment, approximately $0.30 or 4% from net gains related to the sale of an equity investment and market decisions within The US Oncology Network in our Oncology and Multispecialty, and a lower effective tax rate. Turning to second quarter segment results, which can be found in slides eight through 12, and starting with North American Pharmaceuticals, revenues were $86.5 billion, an increase of 8%. This growth reflects a continuation of solid pharmaceutical utilization, including higher volumes from retail national account customers and specialty products. Our ongoing focus on operational excellence also delivered operating expense levers during the quarter.

Revenues from GLP-1 medications were $13.2 billion in the quarter, an increase of approximately $2.6 billion, or 24%, when compared to the prior year. On a sequential basis, GLP-1 revenue increased 6%. Segment operating profit increased 13% to $851 million, driven by growth in the distribution of specialty products to health systems, the impact of new product launches, and continued operating expense efficiencies. In the Oncology and Multispecialty segment, revenues increased 32% to $12 billion, driven by strong provider and specialty distribution growth, including contributions from acquisitions completed in the first quarter of fiscal 2026. The acquisitions of PRISM and Core Ventures contributed approximately 12% of the second quarter segment revenue growth. Operating profit increased 71% to $397 million, driven by increased provider and specialty distribution volumes and contributions from the acquisitions of PRISM and Core Ventures.

These acquisitions contributed approximately half of the segment operating profit growth in the quarter. Second quarter operating profit results also included non-recurring net gains of $51 million from the sale of an equity investment and market decisions within The US Oncology Network. Excluding the impact from the acquisitions of PRISM and Core Ventures and non-recurring net gains, segment organic operating profit increased 13%, highlighting the strength and momentum of the core business. In the Prescription Technology Solutions segment, revenues increased 9% to $1.4 billion, driven by increased prescription volumes across our third-party logistics and technology services businesses. Operating profit rose 20% to $261 million, reflecting increased demand for access solutions, including prior authorization services for GLP-1 medications. Turning to Medical-Surgical Solutions. During the second quarter, we observed softer illnesses and product demand compared to the prior year, including vaccines and testing, and lower volumes across ambulatory and extended care settings.

Revenues were $2.9 billion, flat compared to the prior year. Higher volumes of specialty pharmaceuticals were offset by lower contributions from illnesses and products and testing across the ambulatory and extended care settings. Compared to the prior year, revenues from seasonal vaccines and testing volumes represented an approximate 4% headwind. Operating profit increased 2% to $249 million, driven by operational efficiencies from cost optimization initiatives. This was partially offset by the headwind from lower contributions related to illnesses and products and testing. Wrapping up our review with corporate, corporate expenses were $151 million in the quarter. As a reminder, in the second quarter of fiscal 2025, we recorded pre-tax losses of $15 million, or $0.09 per share, related to equity investments within the McKesson Ventures portfolio, compared to gains of $3 million, or $0.02 per share, in the second quarter of fiscal 2026.

Due to these impacts, corporate expenses were flat compared to the prior year. Return to cash and capital deployment for the second quarter is shown on slide 13. We ended the quarter with $4 billion in cash and cash equivalents, underscoring the strength of our strong liquidity position and capacity to deploy capital in a value-creating manner. Second quarter free cash flow was $2.2 billion, which included $196 million in capital expenditures. This robust cash flow performance reflects disciplined working capital management and continued operating execution strength. During the quarter, we returned $907 million of cash to shareholders, which included $818 million of share repurchases and $89 million in dividend payments. These actions underscore our commitment to balanced capital deployment and long-term shareholder value creation. Before reviewing our updated fiscal 2026 outlook, I'd like to provide two portfolio updates.

At Investor Day in September, we reaffirmed McKesson's long-track record of consistent financial performance, driven by strategic clarity, consistency, and disciplined execution. Our new segmentation reflects the portfolio evolution, leading to sharper strategic focus, enhanced transparency, and increased long-term financial targets. Our strategic clarity and execution position the company to deliver sustained value across multiple environments in different cycles of healthcare, leading to sustained value creation. Let me start with Norway. Our fiscal 2026 outlook contemplates contributions from operations in Norway for the full fiscal year. Beginning in the second quarter of fiscal 2026, we discontinued recording depreciation and amortization on the assets involved in the transaction due to held-for-sale accounting treatment. This resulted in an accretive impact of $0.03 in the second quarter.

For the full year, we now anticipate approximately $0.13 of adjusted earnings accretion due to held-for-sale accounting in fiscal 2026, which compares to our prior guidance of $0.20. Next, we're committed to executing the separation of our Medical-Surgical Solutions business in a tax-free transaction, maximizing shareholder value. Since it was announced in May, we've made significant progress towards establishing the Medical-Surgical business as an independent operating company. As I mentioned at Investor Day, we anticipate exiting the business by way of an initial public offering. Following a customary lockup period, McKesson intends to exit its remaining interest through a spin-off or a split-off transaction, or potentially a combination of both. We currently anticipate that this separation could be completed by the second half of calendar 2027, subject to market conditions and customary regulatory approvals. Our fiscal 2026 outlook assumes 100% ownership of the medical segment.

Our portfolio transformation has delivered consistently outstanding financial results, growth, and returns to shareholders. Now moving to our fiscal 2026 outlook. Our strategy continues to deliver outstanding results, propelled by the growth and differentiation of our Oncology and Multispecialty and biopharma services platforms. These platforms are supported by a durable foundation of distribution assets and capabilities, positioning McKesson for sustained success. At our Investor Day, we raised our earnings per diluted share outlook by $0.80, a range of $38.05-$38.55, which was a testament to the clarity of our strategy, strength of our portfolio, and disciplined execution. Building on our strong second quarter performance and continued confidence in our outlook over the remainder of the year, we're further increasing our fiscal 2026 earnings per diluted share outlook by $0.30 to a new range of $38.35-$38.85, which represents 16%-18% growth over the prior year.

This update builds on the $0.80 increase announced at Investor Day in September. For fiscal 2026, we anticipate revenue growth of 11%-15%, reflecting growth across all core businesses, and operating profit growth of 12%-16%, driven by continued momentum and execution. Let me start with a review of our segments. In the North American Pharmaceutical segment, our core pharmaceutical distribution operations continue to demonstrate a strong and diversified value proposition to customers. We anticipate revenue to increase 10%-14%. We're increasing our guidance for operating profit to 5%-9% growth. The increased operating profit outlook is driven by solid utilization trends, volume growth, and continued strong specialty distribution expansion. In the core distribution business, we also anticipate continued growth of GLP-1 medications. We anticipate this growth may vary from quarter to quarter.

As a reminder, prior year results include the impact of the divestiture of our Canada-based Rexall and Well.ca businesses at the end of the third quarter of fiscal 2025. In the Oncology and Multispecialty segment, we anticipate revenue growth of 27%-31% and operating profit growth of 49%-53%. The guidance includes the acquisitions of PRISM Vision and Core Ventures, completed in the first quarter of fiscal 2026. We are pleased with the performance of these acquisitions. We anticipate that they will contribute approximately 30%-34% to the fiscal 2026 operating profit growth in the segment. Our full year outlook reflects the impact of these acquisitions and strong organic specialty distribution volume growth. Our Oncology and Multispecialty platform continues to deliver across distribution, practice management, data and analytics, and clinical research.

In the Prescription Technology Solutions segment, we anticipate revenues to increase by 9%-13%, and we are increasing the operating profit outlook to 13%-17% growth. The improved operating profit outlook reflects strong organic volume growth and momentum across our access and affordability solutions, particularly higher contributions from prior authorization services, including those related to GLP-1 medications. As I've previously discussed, the revenue and operating profit trajectory in this segment is not linear and may vary from quarter to quarter, driven by several factors, including

utilization trends, the timing and trajectory of new product drug launches, the evolution of a product's program support requirements as it matures, which could result in a shift to other services or a program termination, product delays and supply shortages, payer requirements, including utilization management and formulary strategies, the annual verification programs that we provide for our customers that occur in our fiscal fourth quarter, and the size and timing of investments to support and expand our product portfolio. Moving to the Medical-Surgical Solutions segment. Due to lower-than-anticipated illnesses and product volumes compared to the prior year, including vaccines and testing, and lower volumes across ambulatory and extended care settings, we anticipate revenue and operating profit at the low end of 2%-6% growth.

Illnesses and variability remain a key factor, and the timing and severity level of each illness season can drive variability from quarter to quarter and year to year. We anticipate corporate expenses to be in the range of $600 million-$650 million, which incorporates the impact of $4 million of pre-tax gains related to equity investments within the McKesson Ventures portfolio in the first half of the fiscal year. Turning now to items below the line, we anticipate interest expense to be in the range of $210 million-$240 million. Reduced interest expense target compared to the range provided at Investor Day reflects continued strong debt portfolio management and commitment to maintaining our strong investment-grade credit ratings. We anticipate income attributable to non-controlling interest to be in the range of $215 million-$235 million, which includes the impact from fiscal 2026 acquisitions.

We anticipate the full-year effective tax rate will be in the range of 18%-19%. We also anticipate that the quarterly tax rate will be higher in the third quarter than in the fourth quarter due to the timing of discrete tax items. We anticipate the third-quarter tax rate to be in the range of 23%-25%. Wrapping up our outlook with cash flow and capital deployment. One of McKesson's enduring strengths is our proven ability to consistently generate strong free cash flow and execute value-creating capital allocation. For fiscal 2026, we anticipate free cash flow of approximately $4.4 billion-$4.8 billion. Our outlook includes plans to repurchase approximately $2.5 billion of shares, with estimated weighted average diluted shares outstanding of approximately 124 million. Our strong operating performance, combined with disciplined working capital management, continues to provide ample liquidity and financial flexibility.

We've also strengthened our financial position by reducing leverage and optimizing our debt portfolio over time. Our focused and disciplined approach to capital allocation remains a cornerstone of our strategy and a key driver of long-term shareholder value creation. In summary, McKesson delivered strong second-quarter results, including record quarterly consolidated revenue and double-digit operating profit growth across three segments. Our updated earnings per diluted share range of $38.35-$38.85 reflects both our second-quarter results and our confidence in the business for the remainder of fiscal 2026, as we continue to execute against our strategic and financial framework. The ongoing evolution of our portfolio is aligned with the increased long-term targets that we committed to, and this transformation continues to translate into stronger earnings, higher returns on invested capital, and a fortress balance sheet positioning McKesson for discipline and strategic capital deployment. With that, let's move to the Q&A session.

Thank you. If you would like to signal with questions, please press star one on your touch-tone telephone. If you are joining us today using a speakerphone, please make sure the mute function is turned off to allow your signal to reach our equipment. Again, that is star one if you'd like to ask questions. Our first question will come from Lisa Gill with JPMorgan.

Thanks very much. Good afternoon. Great results again this quarter. Just really want to understand two things. When I look at the revenue growth versus the operating profit expansion, especially in North America's Pharmaceutical as well as Prescription Technology Solutions, I heard what you said, especially in your last comments around it all being organic growth when we think about Prescription Technology Solutions. But is it new products you're bringing to the market? Is it enhanced programs that are driving that margin? If I could just understand really what is happening on the margin profile there. If I go back to your Investor Day, I had thought that you had talked about some incremental investments that you needed to make in that business. How do we just think about the sequential quarters as we go throughout 2026?

Yeah, thanks for the question, Lisa. Let me start with your first question. What we did see in the quarter is a continuation of the strong performance in all of our segments, and we actually saw operating margin expansion in our three core segments. There are a number of things that are driving this. Specifically in the Rx technology business, we are seeing good mix. We are seeing more growth in our technology services components. That is really all of the things that you mentioned.

There are new products and programs that we're seeing growth in, and we're certainly seeing growth in some of our access programs like prior authorizations, particularly for GLP-1. It is a little bit of all of those things that are all driving in the right direction, and the mix from those technology services is driving more margin growth in that segment. As it relates to the investments, yes, you did hear that right, and we do anticipate a higher level of investments in the second half of the year. You think about the cadence for the year, certainly we had very strong operating profit growth in that segment the first half of the year.

We expect that to continue to be strong in the second half of the year, and that's going to be against an increased level of investment spending that we have included in our guidance for the balance of the year. We are really pleased with the performance of the first half of the year, our ability to increase that guidance for the full year, but also while we are making additional investments through the back half of the year.

I would just add that these growth investments have been part of the algorithm for many, many years now, and it's not always linear. It's measured up against what we see as opportunities to continue to innovate, to continue to expand the markets that we can go after and support our future growth. We are actually glad when we have these opportunities.

Next will be Brian Tanquilut with Jefferies.

Hey, good afternoon, guys. Congrats on the quarter. Hey, Britt, maybe just as I think about Oncology and Multispecialty, strong results there, but you're maintaining the guidance. Just curious. Was the beat of the quarter essentially already contemplated in your guide when you did Investor Day and highlighted expectations for that business? Thanks.

Yeah, thanks for that, Brian. A couple of things. We did call out some non-recurring gains. There were three items really that made up that, that all happened in this quarter. The majority of those were known and included in the guidance at Investor Day. There was a third item here that the cadence of that was more back half-weighted in our guidance than we had in Investor Day.

Really, when you break the business down, as I mentioned, the strong growth, about half of that is being driven by the acquisition performance, the two acquisitions that Brian and I both talked about that happened in the first quarter of the fiscal year. Those businesses are performing well. As Brian pointed out, we're adding to that platform on the PRISM platform, and we're pleased to be able to do that. The organic business, as I talked about, is growing at about 13% year-over-year. That's right in line with the long-term guidance that we provided for the segment. We're pleased that not only are we adding from an acquisition perspective some strong assets to the portfolio, but from an organic perspective, the business is performing as we had anticipated.

Next will be Elizabeth Anderson with Evercore ISI. 

Hi, guys. Good afternoon and congrats on the nice quarter. I was wondering if we could double-click on the health system strength you called out in the quarter. Obviously, there was some good strength all around, but I think we do not talk about that business as much, and that seems like it was an incremental source of strength in the quarter. I would be curious if you could talk about that in a little bit more detail. Thanks.

I think we are very pleased with the way our health system business continues to perform. It is a segment of the market that we put some focus on a few years back. We think we are at a point now where we have market-leading share. We think the volumes have been strong in that space. As our customers see strong traffic flow through their settings, we are benefiting from that volume and that expansion. I think it speaks to the quality of the partners that we have in the health system. Thank you for calling that out. We do not often talk about it.

Next will be Charles Rhyee with TD Cowen.

Yeah, thanks for the question. Britt, I might have missed it a little bit before, but when we are thinking about the tax rate for the year, if I remember. When you first gave guidance, you said. You gave the range and said the first half would be higher than the second half and the first quarter higher than the second. Obviously, we saw, I think, was it a little over 21% first quarter? I think it was 17.5% this quarter. Full year, you are still guiding 18%-19%. Actually brought it up towards the higher end. How should we think about tax rate in the back half of the year? Thanks.

Yeah, thanks for that question. Obviously, as we've talked about, the tax rate could vary from quarter to quarter. Not only the mix of income will be an important factor of that, but the timing of discretes. We are anticipating that the second half will have a slightly higher rate than we had in Investor Day. That is what is really driving the guidance from 17%-19% to 18%-19%. That is really just a modest change in our outlook there. As I provided here, we gave you specific tax rate guidance for the third quarter. We anticipate that the third quarter will come in right around 23%-25%. We would anticipate that the timing of some discrete and mix of income will drive a lower rate in our fourth quarter.

Next will be Eric Percher with Nephron Research.

Thank you. There are several macro indicators, especially volume, treatment acuity, that have expanded the last two quarters. I want to ask, do you agree that the trend has been elevated in the first half? Do you expect that the same type of specialty trend continues in the second half of the year if it is at an elevated level? I would also ask, just on the edge of that, can you help decode what a market decision within The US Oncology Network means?

I am not 100% sure I know what dataset or set of statistics you are anchoring your question in, but what I would say is that in our oncology business, we have continued to see good traffic. Volumes in our existing footprint, complemented obviously by the new partners that we bring into the network as we continue to expand. We see good patient flow. Our view of the community setting is it being the low-cost, most accessible, and a high-quality place to receive cancer care. As the network has matured over the years, we find ourselves able to take on and treat more and more complicated oncology-type patients. That has certainly been part of our algorithm. Obviously, if you look at the therapies, the more complicated therapies that are coming to market, that also supports the strength that we've seen in that segment.

Eric, as it relates to your question on market decisions, I mean, we had two things that happened in the quarter. We had the realization of an equity investment that created a gain, and then the market decision aspect. From time to time, we will either enter or exit a market, depending on really the profile of that particular marketplace and how it aligns with The US Oncology market and The US Oncology strategies. In this particular quarter, we exited two markets. From time to time, we will see exits from markets. We'll also see, obviously, entries into new markets. This is unusual in the sense that we had a couple of these items all happen in the same quarter. We do not usually have three of these types of items in one particular quarter.

Yeah, and we're more typically, in our recent history, been adding, but it's important that we maintain the discipline to continually review the portfolio and the footprint of our practices. It's something we'll remain committed to.

Hi, thanks for taking my question. I want to unpack the guidance a little bit, or at least the implied guidance. If I look at the Pharma segment growth in the first half of the year, the actual is north of 11%. And it would imply the second half is less than 4%, 3.5%, roughly. I know there's some investments in spend. Is there anything else to call out incrementally from what you've achieved in the first half of the year versus what would happen in the second half of the year just in the U.S. Pharma segment?

Yeah, Kevin, thanks for that question. I would point to two things. As you may recall, last year, we onboarded a new strategic customer into this segment that started in the second quarter of fiscal 2025. First half of this year would have one incremental quarter of operations from that particular customer. Last year, as I mentioned in my remarks, we exited our Canada-based Rexall and Well.ca businesses. As a result of that, we had some held-for-sale accounting accretion in last year's numbers. Those two things are really the key drivers for the first half versus second half.

Next will be Daniel Grosslight with Citi.

Hi, guys. Thanks for taking the question, and congrats on another strong one here. There has been a lot of chatter about the cash pay channel recently. Folks going away from their insured benefit. For calendar year 2026, if we do see an increase in uninsured and more insured people paying cash for their prescriptions, perhaps through TrumpRx, how do you anticipate that will impact your prior auth business, your RxTS business.

What's contemplated in guidance there? Are you planning to work with the Trump administration to integrate some of your technologies into the TrumpRx website? Thanks.

Sure. Let me start. I mean, the TrumpRx or these direct-to-patient, I think there's been three or four announced as part of the MFN letter that went out from Trump. Our view on these right now is first, step back. There's been direct-to-patient pharmacy for over a decade. I mean, so it's not really new in the marketplace. The view that we would hold right now is that the population that's eligible and can afford even the discounted prices really remains pretty small based on assessment that we've done to this point in time. Therefore, we don't see a big impact on the prior authorization business. As part of our affordability offerings, we do have tools.

We've built these tools that allow us to automate pharmacy, to interface with patients, to support patient inquiries, last-mile delivery. We have a lot of the tools that can play a role, and we are playing a role in some instances in this today. As far as the Trump administration, our commitment is to work with all governments, policymakers, legislators to try to advance the U.S. healthcare system in a way that brings costs down, makes it more accessible for people, and delivers high-quality outcomes. I can't tell you exactly what that might look like, but we are highly engaged at all levels, trying to bring the tools, whether it's in Prescription Technology Solutions or distribution tools, to bear on the challenges that our leaders are trying to solve today.

We think we've got many, many tools and resources that can be important parts of the solutions to those challenges.

Next will be Allen Lutz with Bank of America.

Good afternoon, and thanks for taking the questions. Britt, one for you. This was the third straight quarter where SG&A was down year-over-year, and gross profit is actually accelerating. I know that you don't give quarterly guidance around those metrics or those metrics in general, but it seems like a pretty unique dynamic. You talked a little bit about first half, second half. How should we think about that trend in the first half of the year and the trajectory of gross profit and SG&A into the back half of fiscal 2026? Thanks.

Yeah, thanks for the question. Maybe I'll just start with expenses. If you think about expenses, I did mention that last year we exited our Canada-based Rexall and Well.ca businesses. That is going to have an impact both on the gross profit and the operating expense line. Certainly, operating expenses, you're going to have just a gross amount of operating expenses that leave the business. From a mix perspective, certainly, we have a more favorable mix of businesses now than we did when we had the Canada-based businesses that we sold last year. The other thing I think is important is just our continued focus on efficiency. I talked about how we lead with a technology first and focusing on AI and modernizing our businesses. That is driving a significant amount of operating expense efficiency, which certainly is good for all stakeholders that McKesson deals with.

I think we're very pleased with the quality of the operations and the quality of relationships we have that are driving a more favorable gross margin mix. Certainly, the growth that we're seeing in our technology-based businesses like RxTS, which grew 20% in the quarter, and then the efficiencies that we're seeing in our operating expense leverage.

I mean, this is really, in many ways, some of the manifestation of investments we made in years prior, whether to do physical automation, use digital technologies to automate processes. These are big projects often. They can take years. As they come online, this is the kind of results we expect to see, which is why we think continued investment is a key part of the algorithm.

Next will be Erin Wright with Morgan Stanley.

Great, thanks. A two-parter here. Just first on those gains in terms of rationalization across US Oncology, it sounds like that's purely one-off, but any reason we should anticipate those being more frequent? I assume there's no future contributions anticipated in the guidance today. I wanted to just get an update on PRISM, how that's progressing relative to your expectations now, how you're thinking about opportunities outside of oncology with that in that context. Thanks.

Thanks for your question. I'll start, and then certainly Brian can add on. As it relates to those gains, like I said, from time to time, we will make market decisions that be either an entrance into a new market or an exit from a market. These are non-recurring in nature, and they also included the realization of an equity investment that generated the gains. That is not something that we would

certainly include in the normal operations and normal profit streams, but certainly we wanted to call it out because it was material in the quarter. As it relates to PRISM, we're really pleased with the progress that we've seen. I think the addition of Spokane this quarter is a testament to the fact that we're seeing good progress. We're pleased with the integration thus far, and being able to add to our Vision platform is a testament to that. I think we're really focused on oncology and obviously building out the Vision platform that we've started with PRISM, and we're pretty excited about the progress thus far.

Next will be Stephen Baxter with Wells Fargo.

Hi, thanks for the question. Just to follow up on that, not to belabor the point too much, I think it's pretty clear in terms of these network decisions, what you're actually doing here. But just in terms of the actual items that you recorded in the quarter, I mean, it sounds like the gain was something separate and related to an equity investment. Just trying to understand what the actual economic impact in the quarter is, and is that included in the $51 million that you sized, or is that something that's incremental? Thank you.

Yep, thanks for the question. Just to clarify, the gains and the market decisions together represent the $51 million.

And next will be George Hill with Deutsche Bank.

Yeah, good afternoon. I thought I heard you mention the Drug Supply Chain Security Act in the prepared comments. What I wanted to try to understand, is there any operating impact to this as it relates to the financials? What I think about is sometimes you see regulatory change or technology change, increased customer stickiness, or increased barriers to competition from some of your competitors in the market, especially the second and third-tier guys. I'm just wondering if there's any operating benefit from your guys being able to be agile around the Drug Supply Chain Security Act.

First, I want to recognize the team for what was a very, very complicated technology implementation that was pulled off very, very well. As I mentioned in my prepared remarks, we have had terrific service quality, very, very few disruptions as we've been transmitting the information back and forth to our supply chain partners. I'm very, very pleased with how it's gone.

It was a lot of work in the years leading up to this, and to have it be implemented so smoothly was really good to see and a testament to the great work our teams do. I mean, it is a big investment for the industry. For McKesson, it was. I mean, to that extent, when we talk about the value of the services that we deliver, this just adds another component to that, that a new entrant or someone else would have to replicate and be able to have the capability to participate in this market. Given the structure of our markets, I'm not thinking this is going to be a material driver of anything. Our key focus was to make sure we serve both our upstream manufacturer partners well, our downstream partners well, and that we could transmit the business and keep the supply chain operating reliably, safely, and in compliance with laws. I think we've accomplished that.

Next will be Michael Cherny with Leerink Partners.

Afternoon. Thanks for taking the question. Maybe if I can dial it back to RxTS, I know you highlighted the dynamics you're seeing on the prior authorization work. What are some of the other, call it, mega trends that you're thinking about as you build into not only the performance this year versus in the next couple of years? How do you think about the assets you have right now? Is this something where we could see platform expansion, platform opportunities, either organically or inorganically? Thank you.

There is a lot of conversation going on across the industry right now. A lot relating to the medical parts of the business. We think that the networks we have, both in pharmacy and in the provider base, the technology that we have. What we've done in Rx is take a manual, complicated process that no one was really pleased with and find a way to streamline it, make it better for patients, better for payers, better for pharmacists, take the friction out of that process. We're always on the lookout for processes like that that can avail themselves to us leveraging the same assets we have to solve a slightly different healthcare problem. Our teams are always actively engaged in that. It is one of the strengths of the company as we look at evolutions, external changes, policy changes. We have this very broad, diversified set of capabilities that we can lean in to help address these problems and advance the goals we have for our healthcare system.

Certainly. That question will come from Steven Valiquette with Mizuho Securities.

Great, thanks. I think at the beginning of this fiscal year, you guys provided some color around the accretion from the two acquisitions. I think it was $0.40-$0.60 from Florida Cancer Specialists and $0.20-$0.30 from PRISM. I guess today you're disclosing the two acquisitions combined are going to add, I think it was 30-34 percentage points to operating profit growth. Just curious, are you able to provide more color on just each individual acquisition and how it's performing relative to those original EPS accretion guidance metrics the way things stand right now? Thanks.

Yeah, Steve, thanks for the question. Let me just make one additional comment here. What we've provided you with at 30%-34% is the adjusted operating profit impact. I would remind you that in the acquisition of Core Ventures, we did raise debt against that. We also had some non-controlling interest that goes below the line. That being said, as Brian and I both mentioned, we're really pleased with the progress of both acquisitions. I would say that they're both relatively in line with the guidance that we provided. I would say that PRISM is probably slightly ahead. Certainly our ability to continue to add providers to that platform will only add to that. Both are right, really, in the range that we provided. PRISM may be slightly a little bit ahead of the target that we provided you, but I think the accretion numbers that we gave you still apply. I'd also remind you, we gave you three-year accretion numbers.

McKesson (MCK) Q2 2026 Earnings Call Transcript

Company Participants